Matthew H. Kulke, MD Dana-Farber Cancer Institute
We propose to characterize the response of neuroendocrine tumors to PD-1 inhibition in an ex vivo tissue slice culture model. Using this model, we will assess changes in RNA expression and changes in secretion of key immune mediators in response to treatment. In parallel, we will characterize key secreted immune markers and cytokines in the plasma of patients with advanced neuroendocrine tumors, and assess whether secretion patterns are associated with overall survival. Our findings should provide preliminary evidence of whether immune checkpoint inhibition has a biologic effect on neuroendocrine tumors, and more broadly should provide insights as to the potential role of secreted immune mediators in regulating neuroendocrine tumor growth.
da Silva A, Bowden M, Zhang S, Masugi Y, Thorner AR, Herbert ZT, Zhou CW, Brais L, Chan JA, Hodi FS, Rodig S, Ogino S, Kulke MH. Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas. 2018 Oct;47(9):1123-1129. doi: 10.1097/MPA.0000000000001150.
- State: Massachusetts
- Grant Duration: 1 year
- Awards: No information
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.